Calcilytics offer potential to address significant unmet needs in the asthma therapeutics space, report

The potential approval of anti-asthmatic calcilytics could address significant unmet needs in the asthma space and give sufferers greater control over their condition, a new study indicates.

According to business intelligence provider GBI Research’s latest white paper, current asthma treatment options are adequate for the majority of patients, but there are a number of patients – roughly one in 12 – that do not respond to them and therefore suffer inadequate disease control. According to Asthma UK, although it only applies to a minority of patients, this unmet need accounts for around 90% of global healthcare costs associated with asthma.

Callum Dew, associate analyst for GBI Research, notes: “A number of studies have now begun to demonstrate the direct relationship between calcium sensing receptors (CaSR) inhibition – through the use of calcilytics – and levels of bodily fluid biomarkers. Certain blood and bodily fluid biomarkers are known to be associated with asthma, and furthermore increased levels of expression of these biomarkers can correlate with disease severity.”